Back to News
Market Impact: 0.42
CAPR Shareholder Alert: September 28, 2026 Lead Plaintiff Deadline in Capricor Therapeutics, Inc. Securities Class Action
Source: GlobeNewswire
Legal & LitigationHealthcare & BiotechRegulation & LegislationCompany Fundamentals
A securities class action alleges Capricor Therapeutics downplayed the risk that its Phase 3 HOPE-3 trial was functionally unblinded because of a distinctive hypersensitivity-reaction profile. FDA reviewers subsequently flagged the issue, and Capricor shares fell approximately 78.7%, creating substantial litigation and regulatory risk for CAPR.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.82
Ticker Sentiment
CAPR-0.95
More News
- How the US midterm elections reflected resistance to data centres
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- The AI ‘credit card’ is getting costlier as CoreWeave bond yield tops 16%
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says